About AstraZeneca in Cambridge
Our global headquarters moved to Cambridge in May 2016.
Since then, we have delivered over 130 collaborations with our academic, healthcare and research partners to make life-changing discoveries.
For example, our drug discovery scientists are working with Microsoft to use a cloud-based simulation tool that brings alive the millions of potential changes that make cancer cells multiply uncontrollably, to better understand the disease.
Similarly, scientists from MedImmune and Cancer Research UK are working together to discover and develop novel biologics to treat cancer. Together they are working on a novel target associated with leukaemia and recently started an exciting project looking at the best drug combinations to treat pancreatic cancer.
And a novel agreement is also in place that will give researchers from the University of Cambridge access to key compounds from our drugs pipeline.
Once completed, more than 2,000 AstraZeneca and MedImmune R&D science jobs will be on the CBC site, delivering more knowledge sharing, skills and expertise – and ultimately for pushing the boundaries of science.
Bringing together world-class capabilities
Our new Cambridge site will bring together small molecule and biologics research and development activity across our main focus areas. It will also be home to a wide range of leading scientific capabilities, including:
Our team of world-renowned scientists collaborate to support the identification and validation of targets regulating biological processes which are the fundamental drivers of human disease. Using a variety of tools, including in vivo and in vitro assays and bio-informatic approaches, our scientists rigorously test biological hypotheses across all of our therapy areas in both small molecules and biologics.
Our medicinal chemistry capabilities enable us to integrate structural, pharmacological, pharmacokinetic and toxicological information to support the innovative design of novel chemical compounds. Pushing the boundaries of medicinal chemistry enables the delivery of new candidate drugs into our pipeline, and is the foundation of small molecule drug discovery across the company.
Our Antibody Discovery and Protein Engineering Team applies cutting-edge technologies in the discovery of novel therapeutic biologics to change the lives of patients. The team works collaboratively across all therapy areas, using a range of innovative in-house platform technologies such as phage and ribosome display, Fc engineering and novel peptide discovery methodologies. We have an exceptional track record of delivery, having discovered and engineered almost 100 protein therapeutics that have entered the clinic.
Our translational expertise enables us to accelerate the development of new druggable targets in human disease and select the right patients in early clinical trials. We do this by embedding human target validation earlier in research, taking an innovative approach to clinical trial design and integrating multiple data sources to share timely scientific insights across our focus areas. As a leader in personalised healthcare, we are also committed to matching new medicines to the patients that will benefit the most. We do this by combining our expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers and working with external partners to harness breakthrough technologies, throughout the life-cycle of our medicines.
Our Biopharmaceutical Development team develops the process and analytics to produce and characterise product candidates, including the formulations and drug product forms, for delivering medicines to patients. Working closely with research, the team helps define and select the best product candidates to progress into development.
Our Early Clinical Development team designs and delivers early phase development strategies and exploratory studies that build the credentials of novel targets. Clinical Operations delivers global clinical trials for late stage projects across our pipeline, using both internal and external programme and study management expertise. Our leading expertise in large outcomes trials enables us to deliver multi-country, multi-site studies with thousands of patients, many of which include a personalised approach.
“I love working for MedImmune because of the passion our people have for great science, and our ability to turn this science into life-improving drugs.”
Strengthening our Cambridge presence
We are building on our proud Medimmune heritage in Cambridge. More than two thousand AstraZeneca and MedImmune employees are already based in the city and working to build strong connections within the local scientific community.
Our current Cambridge facilities
High quality lab and office facilities to accommodate our growing presence in the city.
Office facilities located on Melbourn Science Park, accommodating around 400 people from our R&D teams, Global Product and Portfolio Strategy and enabling units.
Office facilities located at Academy House and City House in central Cambridge, providing space for colleagues from Global Medicines Development, Global Product and Portfolio Strategy and enabling units.
Lab and office facilities located on Cambridge Science Park accommodating teams from across our IMED Biotech Unit.
Around 60 AstraZeneca colleagues from our oncology team will be temporarily based in the Cancer Research UK Cambridge Institute on the CBC.
Babraham Research Campus
Lab facilities for IMED Biotech Unit scientists working in Drug Safety and Metabolism and personalised healthcare and biomarkers.
Chesterford Research Park
Located on Chesterford Research Park, the building will provide lab and office facilities for scientists from our oncology and personalised healthcare teams from our IMED Biotech Unit.
Open for innovation
Combining the science in our labs with the great science happening within the Cambridge scientific community will enable us to push the boundaries of science further than ever before. Our IMED Biotech Unit is committed to driving sustainable growth globally through innovation, and their 2017 report showcases many Cambridge examples.
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.